mobilized with chemotherapy chosen for optimal stem cell mobilization and disease control. G-CSF (5 or 10 g/kg BW/d subcutaneously) was started 6 days before scheduled leukapheresis.
Blinded serum samples were analyzed with time-resolved fluoroimmunoassays by measuring uPAR variants concentrations before and after uPAR depletion. 8 Accuracy was determined by measuring recoveries of spiked standards in 20% (vol/vol) serum pool in buffer.
Progenitor cell mobilization was similar in autologous patients (mean CD34 ϩ cell count on the day of leukapheresis, 84 128 Ϯ 15 893/mL [SEM] blood; n ϭ 66) and allogeneic donors (79 470 Ϯ 10 710/mL; n ϭ 21). However, leukocyte counts on the day of leukapheresis were inferior for autologous pts (20.89 Ϯ 1.46/ nL, n ϭ 66, compared with 49.6 Ϯ 2.5/nL in allogeneic donors; n ϭ 28, P Ͻ .001, unpaired t test).
Before G-CSF administration, suPAR(I-III), suPAR(I), or suPA-R(II-III) levels were identical in both groups ( Figure 1A-C) . Serum levels for full-length suPAR(I-III) significantly increased in the pooled allogeneic and autologous group after G-CSF administration ( Figure 1A ), but mean suPAR(I-III) levels were lower in autologous patients than in allogeneic donors. An increase in Figure 1 . Increased suPAR serum levels for donors and patients on the day of leukapheresis after G-CSF administration. Serum samples of allogeneic donors and autologous patients were obtained before G-CSF administration (35 and 22, respectively) and on the day of leukapheresis (34 and 66 patients, respectively) (A-C); suPAR(I-III), suPAR(I), and suPAR(II-III) levels were measured. The boxes extend from the 25th to the 75th percentile with a line at the median. For the paired analysis serum levels of suPAR(I-III), suPAR(I), and suPAR(II-III) from individual allogeneic donors (n ϭ 17) (D-F) and autologous patients (n ϭ 14) (G-I) were plotted before mobilization and on the day of leukapheresis. Number of CD34 ϩ progenitor cells as determined by flow cytometry plotted against full-length suPAR serum levels in allogeneic donors (n ϭ 21; panel J, NS) and autologous patients (n ϭ 66; panel K, NS). *Statistically significant increase (unpaired t test for panels A-C; paired t test for panels D-I). NS indicates not significant. suPAR(II-III) and suPAR(I) levels was found in serum from allogeneic but not from autologous patients after G-CSF ( Figure  1B-C) . In paired samples, G-CSF significantly augmented serum levels of the different suPAR forms in allogeneic donors, confirming recently published results ( Figure 1D-F) . 7 In contrast, however, in serum from the autologous group, neither full-length suPAR(I-III) and suPAR(II-III) levels, nor suPAR(I) levels, increased after chemotherapy plus G-CSF treatment (Figure 1G-I) . Most importantly, serum levels for full-length ( Figure 1J-K) or cleaved suPAR (data not shown) after G-CSF administration did not correlate with CD34 ϩ counts in both groups, but did correlate with leukocyte counts (data not shown).
On the basis of our data, we propose that the leukocyte increase after G-CSF is responsible for higher full-length suPAR serum levels, possibly through G-CSF-mediated induction of proteases in neutrophils. 8 A successful progenitor cell mobilization after G-CSF treatment, as observed in the patient group receiving chemotherapy, does not necessarily correlate with increased suPAR serum levels. 
